MALP-2

Summary

MALP-2 (Macrophage-Activating Lipopeptide-2) is a 2-kDa diacylated lipopeptide originally isolated from Mycoplasma fermentans. It is a prototypic TLR2/TLR6 agonist widely used as an immunological tool and experimental adjuvant. Investigated in preclinical and early clinical settings for antitumor immunotherapy, wound healing, and mucosal vaccine adjuvancy. Not approved for any clinical indication.

Mechanism of Action

MALP-2 is a mycoplasmal lipopeptide that acts as a potent agonist of Toll-like receptor 2 (TLR2) in heterodimer with TLR6, triggering MyD88-dependent NF-κB signaling and pro-inflammatory cytokine production (TNF-α, IL-1, IL-6, IL-12), thereby activating macrophages, dendritic cells, and NK cells. It also stimulates angiogenesis via upregulation of VEGF and other growth factors.

Routes of Administration

Goals & Uses

• Macrophage activation researchImmunology (Research Tool)High
• Wound healing / angiogenesisDermatology / Regenerative MedicineLow
• Antitumor immunotherapyOncologyLow
• Mucosal vaccine adjuvantImmunology / VaccinologyModerate
• Sepsis / innate immune primingInfectious DiseaseLow

Contraindications

• Active sepsis or systemic inflammatory response syndromeInfectious Disease / Critical CareHigh
• Known hypersensitivity to lipopeptidesAllergy / ImmunologyHigh
• Systemic autoimmune diseaseImmunologicalHigh

Adverse Effects

• Fever / PyrexiaSystemicCommon
• Nausea / gastrointestinal discomfortGastrointestinalUncommon
• Cytokine release syndromeImmunologicUncommonSystemic inflammatory response from immune activation
• HypotensionCardiovascularRareLow blood pressure
• Local injection site inflammationLocal / DermatologicCommon

Drug Interactions

• Immunosuppressants (corticosteroids, cyclosporine)Moderate
• NSAIDsLowMay increase renal risk in susceptible patients
• Other TLR agonists (e.g., LPS, CpG)Moderate

Population Constraints

• Pediatric populationsAgeRelative
• Immunocompromised patientsImmunologicRelative
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionInvestigationalEarly-phase clinical trials conducted in Germany (e.g., EudraCT-registered studies in pancreatic cancer); no marketing authorization.
• United StatesUnapprovedNot FDA approved; available only as a research reagent.
• United KingdomUnapprovedNo MHRA approval; research use only.

No regulatory approval in any jurisdiction. Used primarily as a research reagent and experimental immunomodulator. Some early-phase clinical trials conducted in Germany (e.g., pancreatic cancer, mucosal application).

Evidence & Sources

No sources recorded yet.